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activate common systemic inflammatory pathways.
Nosocomial infection, organ failure, and mortality in this
patient population are associated with a quantitatively
different reprioritization of the circulating leukocyte
transcriptome to the initial inflammatory insult, greater
in both magnitude and duration, and secondary to mul-
tiple observed defects in innate and adaptive immune
function. Dysregulation of inflammatory resolution pro-
cesses and associated bioactive lipid mediators (LMs)
mechanistically contribute to this phenotype. Recent
data indicate the potential efficacy of therapeutic inter-
ventions that either reduce immunosuppressive prosta-
glandins (PGs) or increase specialized proresolving LMs.
Here, we reassess the potential for pharmacological
manipulation of these LMs as therapeutic approaches
for the treatment of critical illness (CI).
Inflammation unites CI
Systemic inflammation is nearly ubiquitous in CI, unit-
ing the leading causes of intensive care (ICU) admission
[1]. Induced by infectious and noninfectious stimuli with
approximately equal frequency [2], the host inflammato-
ry reaction is driven by common mediators and shared
signaling pathways [3,4]. Critically ill patients are
now understood to experience a highly coordinated,
reproducible response at the transcriptomic, metabolomic,
and proteomic level, regardless of the inflammatory source
[5–7].
Adverse clinical outcomes are associated with a quanti-
tative dysregulation of the inflammatory profile in both
magnitude and duration [7]. Predominance and prolonga-
tion of anti-inflammatory processes mechanistically contrib-
ute to multiple defects in the innate and adaptive immune
system, and consequent vulnerability to nosocomial [hospi-
tal-acquired infection (HAI)] [8,9] and CI-induced immune
dysfunction (CIIID) [10]. In total, 30% of CI patients will
contract HAI; a rate six times greater than on standard
wards [11,12]. HAI in this setting is associated with a1471-4906
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in excess of 50% [11,13]. Causative pathogens are most
commonly bacterial; however, fungal infections (particular-
ly Candida spp.) are increasing in incidence [12]. Viral
infection, especially reactivation, poses an additional risk,
and polymicrobial infection is common.
LMs, including eicosanoids and the more recently dis-
covered ‘specialized pro-resolution lipid mediators’ (SPMs),
are key signaling molecules in the resolution of inflamma-
tion, playing a pivotal role in regulating the inflammatory
profile and promoting return to homeostasis [14]. Their
dysregulation in any of several dimensions may have
pathogenic consequences (Box 1), with failure of resolution
leading to chronic inflammation and excess tissue damage
being best recognized [14,15]. The potential active contribu-
tion of LMs to an anti-inflammatory, immunosuppressive
phenotype has, until recently, received little attention [10].
Observational studies have related LM-modifying aspi-
rin and statin administration, as well as nonsteroidal anti-
inflammatory drugs (NSAIDs), to clinical benefit in the CI
population (Box 2) [16], and compelling clinical data sup-
port the use of targeted immunomodulatory therapy
[17,18]. This information, coupled with a more advanced
appreciation of how inflammatory resolution pathways,
and LMs in particular, may affect immune competence
(and be used to modify it) in CI, necessitates a reappraisal
of the clinical validity of these drugs.
Here, we summarize contemporary preclinical and clin-
ical data describing the effects of modulating LMs in CI
syndromes, predominantly sepsis. We describe the patho-
genic contribution of two distinct yet interlinked patterns
of dysregulation to CIIID, namely injurious and failed
inflammatory resolution, and discuss therapeutic oppor-
tunities presented by LM manipulation.
CI: a failure of resolution?
v-3-Derived SPMs from different series appear to have
individually separate yet collectively beneficial effects on
multiple modalities of immune function. Evidence indi-
cates that a paucity of these LMs contributes to derange-
ment of the inflammatory profile and CIIID, with
therapeutic replacement restoring or augmenting immune
function. In the next sections we discuss data relating to
specific LMs of the resolvin (Rv) and protectin series, and
later the lipoxin (LX) and leukotriene (LT) families in
interventional animal models of infection/inflammation.
Defining features of SPM bioaction include the ability
to: (i) counter-regulate mediators that summon leukocytes,
Box 2. Observational and mechanistic data supporting
therapeutic LM manipulation
Regular use of aspirin in patients who develop community-acquired
pneumonia has been associated with lower ICU requirement (odds
ratio 0.19, 95% confidence interval 0.04–0.87) and shorter in-patient
stay (13.96.2 vs. 18.210.2 days) [86]. In a general CI patient set
prior prescription and consumption of aspirin and statins has been
linked with reduced severity of illness (development of severe
sepsis, acute lung injury, or adult respiratory distress syndrome)
and mortality in a multivariate analysis [83]. Aspirin administration
within 24 h of SIRS recognition has been separately linked with a
significant decrease in mortality in all such ICU patients of –6.2%
(absolute risk difference after propensity matching), and an even
greater mortality reduction in those with proven sepsis of –14.8%
(27.4% aspirin vs. 42.2% no aspirin) [84]. Independently, a near 50%
reduction in the risk of inpatient mortality in septic patients given
aspirin during their ICU admission has been described [88], with
similar levels of benefits potentially resulting from utilization of
alternative NSAIDs in addition (ibuprofen, diclofenac, or indometha-
cin) [85]. NSAID benefit is however lost if coadministered with aspirin
[85], and concerns regarding delayed presentation [89] and side
effects persist [84]. The cause of clinical improvement is likely
multifactorial and suggested to be secondary to antithrombotic
(antiplatelet), anti-inflammatory effects and augmentation of inflam-
matory resolution pathways [16,87]. This is re-enforced via positive
interactions with statins [83] and other antiplatelet agents [86,87].
Mechanistically, aspirin and statins exert their immunomodula-
tory actions through increased synthesis of bioactive SPMs from all
three PUFAs (Figure 3). Both may modify COX-2 – aspirin via serine
acetylation, and statins via cysteine S-nitrosylation – to generate
15R-hydroxyeicosatetraenoic acid, which is subsequently converted
by 5-LOX into 15-epi-LXA4 (aspirin-triggered LX, ATL). Aspirin may
in addition upregulate expression of the ATL receptor ALX (FPRL1)
[42], and promote the generation of aspirin-triggered Rvs (17R-
epimers) and protectins (e.g., aspirin-triggered protectin D1).
Glucocorticoids have also been demonstrated to increase SPM
generation [79]. The effects of these molecules in models of CI are
discussed in the main text.
Box 1. LMs: background and pathogenic potential
AA (20:6, v-6), docosahexaenoic acid (22:6, v-3) and eicosapentae-
noic acid (20:5, v-3) are polyunsaturated fatty acids that form the
substrates for the enzymatic generation of several groups of
bioactive LMs. Eicosanoids – the generic term for a group of
bioactive lipids containing 20 carbons derived from AA – are divided
into several separate mediator families, the major groups being the
PGs, LTs and LXs. More recently discovered v-3-derived SPM
families include Rvs, protectins, and maresins. LMs represent vital
endogenous biochemical determinants of inflammatory kinetics and
the principle mediators of resolution.
The ability of NSAIDs to reduce the primary symptoms and signs
of inflammation via COX inhibition and hence PG suppression has
led to a common assumption that they, and in turn eicosanoids in
general, are universally proinflammatory. This represents a grossly
simplified view. These lipid mediators are variably constitutive and
inducible, expressed widely yet in a cell-type- and tissue-specific
manner, and their actions are diverse, multifaceted, and vary down
to the receptor level. Individual molecules have been shown to
variably exert pro- and anti-inflammatory effects along with pro-
resolution properties in a context-dependent manner.
Given their immunomodulatory potency and diversity of action,
for an effective and self-limited inflammatory reaction to be
facilitated, eicosanoid generation must be localized, balanced,
proportionate, and timely. Disturbance in any of these dimensions
in isolation, or more likely combination, may contribute adversely to
disease states. Several pathogenic aberrations may be hypothe-
sized:
1) Location of action.
 Compartment leakage or altered distribution of generation.
Endocrine as opposed to typical autocrine or paracrine activity.
2) Increased or decreased concentration.
 Altered synthesis, via host, pathogen or iatrogenic interven-
tion, through modulation of substrate or enzymatic process.
 Promotion or loss of catabolism (local or systemic) or the
failure of feedback loops. Altered bioavailability or protein
binding (e.g., albumin).
3) Deranged temporal profile of production.
 Failure or dysregulation of eicosanoid class switching [64,65].
4) Up- or downregulation of receptors, alteration in receptor profile,
including distribution.
5) Modification of action (e.g., co-stimulation – additive, synergistic,
or anergic) by other stimuli/mediators in the surrounding inflam-
matory milieu.
In broad terms, two key patterns may result from the above. First,
deficient or failed resolution where either an insufficient concentra-
tion of LM are available to facilitate inflammatory termination, or
their action is inadequate. This has been recently discussed in
varying inflammatory conditions [14]. Second, a state we describe
as injurious resolution may exist. Here, an excessive immunoregu-
latory effect is exerted by eicosanoids involved in the initiation or
control of resolution, rendering host defenses locally or systemically
compromised [10].
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to an inflamed site; (ii) dampen pain; (iii) stimulate non-
phlogistic monocyte recruitment; and (iv) activate macro-
phages to efferocytose apoptotic granulocytes and clear both
pathogens and tissue debris [14]. Despite being part of the
endogenous anti-inflammatory process via action (i), with
associated prevention of inflammatory amplification, it is
attributes (iii) and (iv) in tandem with promotion of phago-
cyte trafficking to lymph nodes [19] that distinguishes them
from classical anti-inflammatory mediators such as inter-
leukin (IL)-10 or IL-1 receptor antagonist [14].
SPMs have repeatedly been demonstrated to lack
an immunosuppressive action, and indeed to augment
host-directed antimicrobial defenses [20]. These moleculesstimulate mucosal production of bactericidal peptides [21]
and enhance bacterial phagocytosis by PMNs and macro-
phages, working synergistically with antibiotics, to in-
crease their therapeutic action and hence bacterial
clearance [22]. They have further been shown to suppress
nuclear viral mRNA transcript export, and hence replica-
tion, reducing mortality from influenza infection [23]: a
potentially novel therapeutic addition to standard antivir-
als, focused on modifying host immune capability, avoiding
the problems posed by these infectious agents diversity,
variability and capacity to evolve.
Rvs and protectins
RvE1 administered prior to a murine model of aspiration
pneumonia (hydrochloric acid with subsequent Escherichia
coli challenge) was associated with a reduction in proin-
flammatory cytokines, decreased pulmonary PMN accumu-
lation, enhanced bacterial clearance, and improved survival
[24]. El Kebir and colleagues have further described the
ability of RvE1 to promote resolution of established infective
and sterile models of murine lung injury [25]. Mechanisti-
cally, RvE1 was noted to enhance NADPH-oxidase reactive
oxygen species generation and promote phagocytosis-in-
duced neutrophil apoptosis (with subsequent efferocytosis
by macrophages) via the LTB4 receptor BLT1. Increased
activation of caspase-8 and caspase-3 in tandem with atten-
uation of both extracellular signal-regulated kinase (ERK)13
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the balance of pro-/anti-survival information toward apopto-
sis via induction of mitochondrial dysfunction. In addition,
RvE1, at concentrations as low as 1 nM, enhances macro-
phage phagocytosis, with the products of its metabolism
continuing to exert pro-resolution properties but with re-
duced bioactivity in vivo [26].
RvD1 pretreatment prior to lipopolysaccharide (LPS)-
induced acute lung injury is protective, improving patholog-
ical changes and survival [27]. The central mechanism
appears to be suppression of nuclear factor (NF)-kB activa-
tion in a partly peroxisome proliferator-activated receptor
(PPAR)g-dependent manner, with associated reduction in
downstream signaling/transcriptomic alteration [28]. RvD2,
but not its isomer trans-RvD2, has been shown specifically to
improve survival in murine polymicrobial sepsis (cecal-liga-
tion and puncture; CLP). Its actions appear multifaceted –
modulating leukocyte–endothelium interactions in a direct
(adhesion receptor expression) and indirect manner (endo-
thelial NO production), altering the cytokine profile [reduced
IL-17, IL-10, PGE2 and LTB4], and enhancing bacterial
phagocytosis and intraphysosomal vacuolar production of
reactive oxygen species [20]. More recently, the ability of
RvD2 to restore neutrophil directionality, prevent CIIID,
and thus increase survival from a secondary septic challenge
post-burn injury has been demonstrated [29].
Discrete specialized pro-resolution mediators are unlike-
ly to be produced in isolation and have overlapping proresol-
ving actions. RvE1, aspirin-triggered (ATL, 15-epi-lipoxin
A4) and protectin D1 may independently rescue cyclo-oxy-
genase (COX)- and lipoxygenase (LOX)-derived ‘resolution
deficits’ in vitro and in vivo, with actions extending to
promotion of phagocyte trafficking away from the primary
inflammatory site [19]. The ability to bind and act as ago-
nists on alternate SPM receptors (e.g., RvD1 on the LXA4
receptor [27]) may provide one pharmacological explanation
for this phenomenon. However, despite their common
actions the source of different classes of SPMs in inflamma-
tion appears diverse. Recent evidence suggests that RvE1
and 2 are synthesized by PMNs via the 5-LOX pathway [30],
whereas eosinophils are responsible for generation of 12/15-
LOX-derived mediators protectin D1 and the newly discov-
ered RvE3 [31,32]. Deficiency of these cell types in the
resolution phase may lead to impaired biosynthesis with
deleterious consequences [31]. The same may be true of
polyunsaturated fatty acids at the inflammatory site.
Experimentally, the v-3 Rv precursors eicosapentaenoic
and docosahexaenoic acids have been demonstrated to in-
crease in exudates during the resolution phase; being both
plasma (partially bound to leaked albumin) and locally
derived [14,33]. Indirect evidence to support the therapeutic
benefit of increasing this SPM series concentration in
humans comes from the addition of fish oils to parenteral
nutrition in septic patients. A raised plasma eicosapentae-
noic concentration was observed along with modification of
the cytokine profile, and small physiological and clinical
benefits in a recent randomized clinical trial [34].
LTs and LXs
Therapeutic use of the arachidonic acid (AA)-derived LX
series may also be beneficial. Post-insult treatment with14LXA4 has been demonstrated to limit inhaled LPS-induced
lung injury [35], and to reduce pro- and anti-inflammatory
cytokine production, enhance macrophage recruitment,
reduce blood bacterial load, and improve mortality in a
rat CLP model [36]. In this later study, macrophage re-
cruitment was increased without impairing phagocytic
function, and systemic inflammation reduced without in-
creasing bacterial spread, mirroring the previously de-
scribed observations with other SPMs [20,24].
A similar paradoxical relation between an attenuated
innate immune response (PMN trafficking to the infected
site), yet efficacy of the overall inflammatory process, as
determined by survival, has been demonstrated in both
wild type mice treated with MK 886 (a 5-LOX inhibitor)
and in 5-LOX-deficient mice [37]. This effect could be
partially replicated if antagonists of cysteinyl-LTs (a fami-
ly including LTC–F4) were given, but crucially not with
antagonism of the classically proinflammatory LTB4. This
elegantly demonstrates the hierarchical, multifaceted and
often opposing effects of eicosanoids in sepsis. In this
setting it appears that the prevention of the cysteinyl-
LTs deleterious effects on the vasculature, hence host
hemodynamics, assumes primacy as the main cause of
benefit in 5-LOX antagonism. By contrast, selective
LTB4 inhibition prior to and post-CLP appears to have
little effect on vascular tone and permeability, but may
blunt the innate immune response – specifically neutrophil
trafficking – exacerbating the infective insult [38,39].
The complex interplay between AA-derived LMs in sepsis
has also been highlighted in recent data showing that flavo-
coxid, a dual COX-2 and 5-LOX inhibitor, reduces the expres-
sion of NF-kB, COX-2, and 5-LOX with improved survival in a
murine CLP model [40]. Plasma IL-10 and LXA4 concentra-
tions were increased while tumor necrosis factor (TNF)-a, IL-
6, LTB4, and PGE2 were decreased. Whether the observed
improvement in outcome was due to enhanced pro-resolution
effects driven by increased LXA4, decreased cytokine storm
(TNF-a and IL-6), augmentation of the immune response via
reducing PGE2 and 5-LOX derived LTs (discussed below),
selective shunting of AA down the COX or LOX pathways, or
a combination of the above is unclear.
Separately, biologically active ATL and aspirin-trig-
gered Rvs have been noted to have pro-resolution effects,
inhibiting leukocyte trafficking in a NO-dependent manner
in both murine [41] and human [42] inflammation, and
downregulating superoxide production in neutrophils
along with macrophage inflammatory peptide 2 and IL-
1b production [43]. The importance of ATL and LXA4
inhibitory stimulation has been previously demonstrated
in CI; its absence leads to unbridled inflammation and
elevated mortality in animal models of infection due to
dendritic cell (DC) hypersensitivity [44].
Thus, accumulating evidence supports the notion that
SPMs are both necessary to the host immune response and
beneficial in severe inflammatory states. Increasing LX,
Rv, and protectin concentrations augments host defense
and improves survival in preclinical models of CI via
multimodally enhancing innate immune function and ame-
liorating CIIID. The immunomodulatory actions of SPMs
on inflammatory resolution processes are summarized in
Figure 1.
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Figure 1. Immunomodulatory effects of two broad classes of lipid mediators throughout the inflammatory response. Persistence or excessive levels of cyclooxygenase-
derived prostanoids and leukotrienes due to a failure to class-switch may contribute to injurious resolution. Here, mediators designed to promote inflammatory resolution
multimodally drive an immunosuppressive, anti-inflammatory phenotype leading to susceptibility to secondary nosocomial infections (highlighted in red). Predominantly
v-3 polyunsaturated fatty acid lipoxygenase-derived specialized proresolving lipid mediators nonphlogistically augment key processes in inflammatory resolution. An
absence or deficit of these eicosanoids may lead to chronic inflammation, failure of pathogen clearance, and both local or distal tissue damage.
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The majority of the interventional studies described above
have used a paradigm of substrate supplementation, direct
molecule addition, or aspirin-augmented biosynthesis to
highlight the benefits of SPMs in CI. Their pathogenic
contribution to severe inflammatory states thus appears
to be one of absence or insufficiency. Conversely, excess
(absolute or relative) or persistence of early-phase resolu-
tion-regulating LMs, specifically prostanoids, may be
equally deleterious to host immune function: a state of
‘injurious resolution’ [10]. The negative immunomodulato-
ry effects of PGE2 [45], PGD2 [46], and the cyclopentenone
PGs of the J2 series [47] have recently been reviewed and
are not described in detail here. Indications of their role in
CI is consequently derived from the reverse methodology –
their reduction or antagonism. Specifically ‘two-hit’
inflammatory/infective insult models may be of particular
relevance to studying CIIID [48].Severe inflammatory stress in mice is associated with a
predominantly anti-inflammatory state and relative immu-
nosuppression following the initial proinflammatory re-
sponse. This is characterized by increased susceptibility
to and worse outcomes from infection [48–50], mimicking
clinical observations [51]. Vulnerability to secondary infec-
tive challenge (replicating HAI) is dependent on time post-
initial insult, decreasing with increased temporal separa-
tion [49,50], and may be reduced by therapeutic strategies
designed to restore immune function [49]. PGE2 appears to
be a key mediator of this phenomenon. Bronchoalveolar
lavage fluid in mice subjected to pulmonary Aspergillus
fumigatus conidia challenge post-CLP contains higher
amounts of PGE2, the production of which seems dependent
upon both alveolar macrophages and epithelial cells [52].
Treatment with ketoprofen, a nonselective COX-inhibitor,
after CLP, but prior to fungal challenge, reduced the PGE2
concentration by >95%, enhanced neutrophil recruitment,
macrophage phagocytosis and proinflammatory cytokine15
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prostanoid (EP)4 receptor in particular was described as
playing a pivotal role [52].
These data support previous work also demonstrating the
efficacy of COX-2 inhibition (NS-398) in attenuating pro-
longed, excessive PGE2production secondary to an alternate
severe inflammatory stressor (trauma/hemorrhage), with
resultant reduction in mortality from subsequent infective
challenge [53,54]. In addition to EP4, a PGE2–EP2–cAMP
axis also appears to contribute to reduced effector cell func-
tion, with both specific EP2 receptor antagonists or EP2-
deficient mice preventing PGE2-induced impairment of both
Fcg-receptor-dependent phagocytosis and NADPH-oxidase-
mediated bacterial killing [55,56].
The temporally defined window of immunosuppression
is matched by sequential alterations in COX-2 expression
and PGE2 synthesis. Higher circulating plasma concentra-
tions of PGE2 are observed on both Days 1 and 7 post-
severe inflammatory stress compared to controls, indicat-
ing exaggerated and prolonged prostanoid production [54].
Correspondingly, splenic macrophages have increased
COX-2 mRNA induction in response to LPS stimulation
even at Day 7 [53,54]. Increased PGE2 concentrations may
alternatively stem from selective induction of microsomal
PGE2 synthase (mPGES)-1 by CI states independent of
COX-2 expression [52]. In comparison, peritoneal neutro-
phils from burn-injured animals have been reported to
exhibit a late-phase decrease in COX-2 expression and
PGE2 synthesis, coupled with a lack of induction to sec-
ondary infective challenge [57], likely indicating compart-
mentalization of the inflammatory response [58,59].
AA release and its COX-mediated metabolism are also
modified by CI in humans. In patients with fracture or burn
injury, peripheral blood mononuclear cells exhibit increased
COX-2 mRNA and PGE2 synthesis in response to LPS
stimulation [60]. By contrast, COX-2 gene expression in
septic patients is reduced such that both basal circulating
concentrations of its metabolites (including PGE2), and
those induced by LPS stimulation of blood leukocytes ex
vivo, were lower than in healthy controls [61]. Furthermore,
the degree of AA-metabolism derangement was associated
with disease severity (greater in septic shock vs. severe
sepsis), and failure of its recovery between admission to
ICU and Day 3 post-admission was predictive of adverse
clinical outcome (prolonged admission or death). The
authors speculate that reduced prostanoid generation forms
part of the anti-inflammatory CIIID phenotype. In attempt-
ing to reconcile these data, we propose two alternative but
interlinked explanations: (i) that altered AA metabolism
and PGE2 generation in the blood compartment represents
an adaptive change to prevent systemic inflammation
[58,62]; or (ii) a response to excess production extravascu-
larly (i.e., the primary infective/inflammatory site). Up- and
downregulation of prostanoid receptors has been observed
in CI humans [60], along with alterations in COX-2 and
mPGES-1 expression [61], indicating a dynamic, responsive
system. Late-phase immunosuppressive mediators are
thought to arise from tissue-resident macrophages in vivo
[63]. Chronic release into the circulation and endocrine
action initiated by the primary event may be expected to
induce compensatory adaptions in blood leukocytes.16The above data indicate that, contrary to popular con-
ceptions, COX-derived eicosanoids, and in particular PGE2,
have significant anti-inflammatory and immunosuppres-
sive effects. In both animal and human studies, CI induces
alteration of prostanoid production. Sustained or excessive
production of these resolution-regulating eicosanoids may
be pathogenic through increasing susceptibility to second-
ary infection. The efficacy displayed by COX inhibition in
clinical observational studies and either COX inhibition or
PGE2 antagonism in preclinical work warrants further
investigation. The immunomodulatory actions of COX-de-
rived eicosanoids are summarized in Figure 1.
A single or dual defect?
It is unlikely that either an excess of immunosuppressive
eicosanoids or a deficiency of specialized pro-resolution
mediators exists independently in CI; their production being
inextricably interlinked. Over the course of the inflamma-
tory response, LM profiles undergo a ‘class switch’ from
initial-phase COX-derived PGs and LTs to specialized
pro-resolution mediators of the LX, Rv and protectin series,
with PGE2 playing a controlling role [64,65]. In particular,
there is now evidence to suggest that different phagocytic
cell types and their subpopulations display specific eicosa-
noid profile signatures that are dynamically altered at
defined intervals throughout inflammation, influenced by
the surrounding milieu and ingested material [66].
Recent data demonstrate that severe inflammatory
stress undermines these normally tightly regulated reso-
lution programs. In a murine peritonitis model contrasting
low-dose, self-resolving inflammation with high-dose, non-
resolving inflammation (10 mg vs. 1 mg zymosan), sus-
tained high amounts of PGE2 and LTB4 (>5 normal)
were reported in the high-dose exudates, along with per-
sistently compromised specialized pro-resolution mediator
production (LXA4, protectin D1 and Rvs 3-fold less than
normal concentrations) [67]. Alterations in miRNA expres-
sion, specifically miR-219-2, and subsequent target gene
expression were implicated. This situation appears analo-
gous to the dysregulated transcriptomic and inflammatory
response associated with adverse outcomes in CI [7].
Humans display different inflammatory response profiles
to set stimuli that are largely determined by resolution
processes and mediators, broad categories of ‘resolution
phenotype’ being established preclinically [68], and tenta-
tively in various clinical settings [69,70]. We speculate that
inflammatory stress of sufficient magnitude in individuals
rendered susceptible via their resolution phenotype may
trigger both higher and persistent amounts of initial-phase
eicosanoids with concomitant failure of specialized pro-
resolution mediator generation, leading to both injurious
and failed resolution (Figure 2). Such dysregulation of LM
synthesis may both exacerbate the acute systemic inflam-
matory response syndrome (SIRS) and subsequently con-
tribute mechanistically to late-phase CIIID [10].
Harnessing therapeutic opportunities
The recognition of aberrant inflammatory resolution
pathways as a contributory factor to the CI clinical pheno-
type opens several translational therapeutic avenues
(Figures 2 and 3).
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Figure 2. Proposed dysregulation of resolution-phase lipid mediators in critical illness. Solid lines indicate the normal inflammatory profile, with an early rise in
cyclooxygenase (COX)-derived prostaglandins (PGs) and 5-lipoxygenase-derived leukotriene B4, which trigger a subsequent rise in specialized proresolving lipid mediators
(SPMs) including lipoxins, resolvins, and protectins. Dashed lines display the altered profile of eicosanoids in critical illness-induced immune dysfunction, with persistence
of early-phase lipid mediators that exert negative immunomodulatory effects and a paucity or relative insufficiency of SPMs, which nonphlogistically augment several key
resolution pathways including bacterial clearance. The combination of this dual defect contributes to vulnerability to hospital-acquired infection. Identification of aberrant
eicosanoid profiles in critically ill patients may allow their therapeutic correction or antagonism to ameliorate effector cell functional impairment as indicated by the dotted
lines.
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cessation of, or alteration in, the use of existing therapies
and/or practices that impair the resolution phase, or cause
its dysregulation. Candidate drugs may be identified via
resolution indices (for example [19]) in standardized mod-
els. Widely used drugs in anesthetics and critical care have
already been implicated [71], and the use of alternate
agents or the same drugs at appropriate phases of inflam-
mation may be advocated. As an example, NSAIDs may
adversely blunt the initial inflammatory response through
impairment of proinflammatory mediator generation, but
may hypothetically be used to ameliorate the late immu-
nosuppressive contribution of COX-derived prostanoids,
especially PGE2, to CIIID [52–54,72].
The potential for both immunostimulatory and immu-
nosuppressive agents in the management of CI in general,
and sepsis in particular, is well recognized and multiple
potential targets have been identified (see [73] for recent
review). Real-time immunological assays to determine
host immune competence and guide immunomodulatory
therapeutics have already shown promise in both experi-
mental [74] and clinical [17,18] studies. As already dis-
cussed, interindividual variance in inflammatory
response to a given stimulus may partly be attributed to
expression of pro-resolution processes [68]. Eicosanoidserum concentrations, in-vitro/ex-vivo functional assays
and flow cytometry may be used to stratify patients into
those who will benefit from targeted interventions to correct
resolution aberrancies: a form of individualized medicine
[75]. Evidence that such a strategy may be effective is
already available: a subgroup of patients in the major
randomized controlled trial of ibuprofen in sepsis who
exhibited exaggerated prostanoid production displayed re-
duced mortality secondary to COX inhibition (Box 3) [76].
The administration of SPMs or their precursors, as
either replacement for a lack of endogenous production
for instance, from a failure to ‘class switch’ [64,67], or as a
supplement to host-generated mediators [20] in the face of
an acute increase in catabolism [26], offers one strategy to
combat failure of inflammatory resolution. Oral adminis-
tration of eicosapentaenoic and docosahexaenoic acid have
already been shown to increase plasma levels of SPMs to
clinically relevant levels [77]. Alternatively, the use of
drugs that act as resolution agonists may prove advanta-
geous (Figure 3). In particular, there is compelling evi-
dence that aspirin [42], statins [78], and potentially
glucocorticoids [79] increase the generation of SPMs or
their equally bioactive epimeric forms to augment aspects
of innate immune function and promote the resolution of
inflammation (Figure 1).17
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matory site will be key to the efficacy of these therapeutic
strategies. As Ricciotti and FitzGerald observe ‘it is one
thing to show that putative pro-resolution products can be
formed in vitro and that the synthetic compounds do exert
pro-resolution actions when administered in vivo and an-
other to document that the concentrations formed in vivo in
the setting of inflammation are sufficient and necessary to
mediate resolution’ [80]. Recent reports describing the
isolation of high levels of SPMs in discrete human biologi-
cal samples that follow predictable, modifiable, temporal
profiles however partially allay these concerns [77,81].
Data suggesting SPMs may be exploited by pathogens in
supraphysiological levels to induce a survival advantage
(Box 4) indicates that attempts to exploit their therapeutic
potential must not inadvertently induce a state of injurious
resolution. Further caveats are discussed below.
The inhibition or antagonism of early-phase eicosanoids
contributing to CIIID, the corollary and complementary
strategy of ameliorating injurious resolution (Figure 2),
may yet prove more tractable. As the above discussion has
indicated, a growing body of evidence suggests that PGE2,
PGD2, 15d-PGJ2, and LTB4may be viable targets, whether18through inhibition of enzymatic synthesis, enhancement of
catabolism (e.g., via albumin), receptor antagonism, or
monoclonal antibody therapy. Translational potential will
be predicated upon description of both local and systemic
eicosanoid profiles induced by severe inflammatory stress,
establishment of robust and generalizable resolution indi-
ces in health and disease to gauge pathogenic dysfunction,
and the trialing of pharmacological agents capable of
selectively modifying PG and LT concentrations in rele-
vant compartments.
Immunomodulatory drugs offer two clear advantages
over current management of CIIID and subsequent HAI.
The first is the ability to prevent infections prophylactical-
ly. Corrective therapy may be administered throughout
ICU admissions to achieve a minimum baseline immune
functional status, preventing new invasive pathogens from
gaining traction. The second is their ability to support
bacterial killing in an antibiotic-independent manner via
augmenting innate immune function. Antibiotic resistance
is one of the greatest challenges facing humans and poses a
particular problem in the ICU patient cohort. Strategies to
both therapeutically enhance pro-resolution activity [22]
and reduce prostanoids-driven injurious resolution [82]
Box 4. Pathogen modulation of LM profiles
The exploitation of LM properties by multiple pathogens under-
scores their biological potency and the potential pathogenicity of
their dysregulation.
Both Toxoplasma gondii and Pseudomonas aeruginosa have
been shown to utilize their independently generated 15-LOX
variants on host substrate (AA) to create a microenvironment with
supraphysiological concentrations of LXs, blocking DC activation
and preventing their phagocytosis [93,94]. Mycobacterium tubercu-
losis (MTB) has been demonstrated to support replication and
immune evasion via a similar yet distinct mechanism. Protective
circulating levels of (anti-inflammatory) LXs appear to be generated
via MTB stimulation of host biosynthesis (as opposed to via
pathogen-generated enzymes). 5-LOX-deficient mice consequently
displayed enhanced T helper (Th)1 responses and lower bacterial
burden than wild type controls; a protective phenotype abolished by
administration of a stable LXA4 analog [95]. Other authors have
demonstrated the opposite of this effect – diminished Th1 responses
(lower IL-12 and g interferon) and consequent survival in tubercu-
losis-infected mice treated with MK 886 [96]. It seems likely that both
early inhibition of pro-inflammatory LTB4 and subsequent excessive
LXA4 may be pathogenic in this setting. This demonstration of the
importance of both pro- and anti-inflammatory LOX products in
mounting a successful defense against invading pathogens has
recently been elegantly supported by work in zebrafish [97].
A further eicosanoid contributor to the pathogen–host interaction
is PGE2. PGE2 production triggered by virulent but not avirulent
MTB has been implicated as a pathogen-defense mechanism, with
PGE synthase/ mice having significantly higher bacterial burden
post-challenge as a result of a shift in macrophage fate profile [98].
In addition, the fungi Candida albicans and Cryptococcus neofor-
mans secrete PGE2 [99] as a virulence mechanism [100]. In this
context, PGE2-mediated inhibition of the transcription factor inter-
feron regulatory factor (IRF)4, with resultant decrease in Th17 cell IL-
17 production during cell differentiation was implicated. Blockade of
host PGE2 in mice infected with C. neoformans led to increased
survival [100].
Box 3. History of COX inhibition in CI
The concept of using COX inhibition in the setting of CI –
predominantly sepsis – is not new; the first experiments being
performed in the 1960s utilizing aspirin. Since then a vast amount of
data has accumulated. Although animal work has been over-
whelmingly positive, COX inhibition pre- or post-septic challenge
improving survival in >70% (31/43) of publications and being
detrimental in only 6.9% (3/43) [72], this success has not been
replicated in humans. The largest randomized controlled trial
showed no significant improvement in sepsis-related mortality
(37% ibuprofen vs. 40% placebo) despite demonstrable prostanoid
suppression and improvement in physiological variables [90]. Two
further smaller studies also showed no effect on mortality
(ibuprofen [91] and lornoxicam [92]). All trials have however
supported the safety of NSAID use in CI and fears that COX
inhibition via aspirin or NSAIDs may predispose to severe sepsis
have not been substantiated [89].
Why then has this preclinical promise not been fulfilled? Many of
the standard difficulties of ICU and sepsis trials apply to these
studies. Investigated populations were heterogeneous in age,
infection site, causative pathogen, and comorbidity burden, produ-
cing a high noise-to-signal ratio. Enrollment over a range of time-
points post acquirement of infection was inevitable, preventing
standardized intervention in the same phase of disease and
potentially missing a narrow therapeutic window where adverse
outcomes may be averted. Trial design was imperfect, the major
randomized controlled trial being underpowered, aiming to detect
an unrealistic 35% difference in mortality [16]. Most importantly, we
now understand that the rationale behind the therapeutic strategy
may have been flawed. NSAID therapy was directed at the
proinflammatory phase, aiming to ameliorate SIRS not CIIID, and
given to a diverse patient set in a nonstratified manner [73].
Re-evaluation of the previously described publications supports
this view. A greater beneficial therapeutic effect (survival) of NSAIDs
was observed in animal models involving live pathogens than in
those where pathogen-associated molecular patterns (PAMPs; e.g.,
LPS) were administered alone [72]. This differential and enhanced
efficacy may be explained by suppression of immunosuppressive
eicosanoids and consequent augmentation of innate immune
function, as opposed to abrogation of their negative physiological
effects, which would be equivalent in both live pathogen and PAMP
models. Furthermore, subgroup analysis of the primary randomized
controlled trial showed a significant improvement in mortality from
hypothermic sepsis (54% vs. 90%) in those treated with ibuprofen
[90]. This presentation was associated with an exaggerated
prostanoid response on admission to the study [76]; a suggestion
that had laboratory-based testing been used to target therapy at a
more immunologically homogeneous population, a beneficial
signal could have been detected.
Pharmaceutical trial evidence targeting the inflammatory cascade
in CI has been instructive largely through its failure. Novel
immunomodulatory approaches aiming to reduce late-phase mor-
tality in stratified patient populations have already demonstrated
promise [17,18,75]. Discarding NSAIDs – a relatively safe, cheap, and
potentially efficacious class of drugs – based on limited data seems
naı¨ve. Further investigation may yet establish therapeutic eicosa-
noid manipulation as part of an immune-restorative arsenal in CI.
Review Trends in Immunology January 2014, Vol. 35, No. 1have recently demonstrated preclinical success in lowering
antibiotic requirements and/or increasing their efficacy. It
is currently unknown if these will translate into the clinical
setting.
Concluding remarks
An excessive dysregulated inflammatory response is asso-
ciated with adverse clinical outcomes in CI patients. Reso-
lution-regulating lipid mediators contribute to this
phenomenon being mechanistically involved in CIIID via
both sustained production of early-phase prostanoids, (inparticular PGE2) and reduced or insufficient late-phase
SPMs.
Resolution therapies, rectifying LM profiles, are pre-
dicted to restore innate immune function, reducing sus-
ceptibility to HAI and its sequelae. To be proven clinically
effective they will have to avoid the pitfalls that have
befallen multiple pharmacological agents in CI, including
previous trials of NSAIDs in sepsis (Box 3). Patients will
have to be stratified and appropriate therapy delivered
according to real-time assessments of inflammatory status
(pro vs. anti), immune functional defects, and causative
mechanisms. Therapy will ideally be targeted at specific
biochemical pathways (e.g., PGE2-EP2/4 blockade as op-
posed to nonspecific COX-inhibition), and guided by quan-
tifiable outcomes [17] in order to reduces off-target effects
and minimize potential toxicity. Equally, a ‘magic bullet’
should not be expected. LM manipulation may form one
part of multimodal immunomodulatory therapy, working
synergistically with other agents. Finally, diverse demo-
graphic, clinical, and microbiological considerations may
also modify treatment decisions. Although these stipula-
tions ensure drug development will undoubtedly repre-
sent a substantial challenge, the chances of developing an
effective therapy are significantly higher as a result. The
potential clinical benefit suggested by observational data
provides sufficient justification to pursue this strategy
[83–88].19
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